New Risk • Apr 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€1.3m net loss in 2 years). Market cap is less than US$100m (€18.2m market cap, or US$21.4m). Buy Or Sell Opportunity • Jan 05
Now 34% overvalued after recent price rise Over the last 90 days, the stock has risen 23% to €0.56. The fair value is estimated to be €0.42, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 0.7% in 2 years. Earnings are forecast to grow by 73% in the next 2 years. Duyuru • Dec 31
Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million. Pet Being agreed to acquire 55% stake in Bau Cosmesi from Farmacosmo S.p.A. (BIT:COSMO) and Andrea Bianchi for €5.1 million on December 30, 2025. A cash consideration of €4 million will be paid by Pet Being. Pet Being will pay an earnout/contingent payment of €1.1 million cash. As part of consideration, €5.1 million is paid towards common equity of Bau Cosmesi.
The transaction is subject to approval of offer by target shareholders.
illimity Bank S.p.A. acted as financial advisor for Farmacosmo S.p.A. Lovells Studio Legale acted as legal advisor for Farmacosmo S.p.A. Gitti And Partners Studio Legale Associato acted as legal advisor for Pet Being. Italaudit SpA acted as due diligence provider for Pet Being. New Risk • Dec 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€4.6m). Currently unprofitable and not forecast to become profitable over next 2 years (€1.3m net loss in 2 years). Share price has been volatile over the past 3 months (5.4% average weekly change). Market cap is less than US$100m (€17.6m market cap, or US$20.7m). Duyuru • Dec 17
Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million. Farmacosmo S.p.A. (BIT:COSMO) agreed to acquire remaining 33% stake in Farmacia De Leo S.R.L. for €2.1 million on December 15, 2025. A cash consideration of €1.8 million will be paid by Farmacosmo S.p.A. Farmacosmo S.p.A. will pay an earnout/contingent payment of €0.3 million cash. Upon completion, Farmacosmo S.p.A. will own 100% stake in Farmacia De Leo S.R.L. In related transaction Farmacia De Leo Srl sold the physical pharmacy business unit to Nica Sgroi Srl.
The effectiveness of the transaction is subject to obtaining authorization for the transfer of the physical pharmacy from the competent authority. Buy Or Sell Opportunity • Oct 20
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 16% to €0.43. The fair value is estimated to be €0.56, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 85% in the next 2 years. New Risk • Jul 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-€3.1m). Currently unprofitable and not forecast to become profitable over next 3 years (€150k net loss in 3 years). Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€22.9m market cap, or US$27.0m). Price Target Changed • Jun 05
Price target decreased by 11% to €1.25 Down from €1.40, the current price target is an average from 2 analysts. New target price is 112% above last closing price of €0.59. Stock is down 30% over the past year. The company is forecast to post a net loss per share of €0.04 next year compared to a net loss per share of €0.077 last year. Duyuru • Apr 15
Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025 Farmacosmo S.p.A., Annual General Meeting, Apr 28, 2025, at 08:00 W. Europe Standard Time. Reported Earnings • Apr 14
Full year 2024 earnings released Full year 2024 results: Revenue: €64.3m (down 11% from FY 2023). Net loss: €2.97m (loss narrowed 8.0% from FY 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Specialty Retail industry in Italy. New Risk • Nov 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.6% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€432k net loss in 2 years). Market cap is less than US$100m (€15.1m market cap, or US$16.0m). Price Target Changed • May 02
Price target decreased by 21% to €1.40 Down from €1.77, the current price target is an average from 2 analysts. New target price is 58% above last closing price of €0.88. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.08 next year compared to a net loss per share of €0.083 last year. New Risk • May 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€7.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€7.0m free cash flow). Earnings have declined by 72% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€1.0m net loss in 3 years). Share price has been volatile over the past 3 months (6.4% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€34.3m market cap, or US$36.6m). Major Estimate Revision • Apr 30
Consensus revenue estimates decrease by 24%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €97.2m to €73.5m. Specialty Retail industry in Italy expected to see average net income growth of 156% next year. Consensus price target down from €1.77 to €1.66. Share price fell 2.6% to €0.88 over the past week. New Risk • Apr 24
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Market cap is less than US$100m (€35.2m market cap, or US$37.7m). New Risk • Jul 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (€38.8m market cap, or US$42.9m). Board Change • Feb 15
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Director Dorothy Rubeis was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Feb 04
Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi. Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million.Farmacosmo S.p.A. completed the acquisition of an unknown majority stake in Bau Cosmesi on February 3, 2023. Duyuru • Jan 10
Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi. Farmacosmo S.p.A. agreed to acquire an unknown majority stake in Bau Cosmesi on January 9, 2023. As of December 31, 2022, Bau Cosmesi recorded revenues of over €0.3 million. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Mar 31
Farmacosmo S.p.A. has completed an IPO in the amount of €22.999905 million. Farmacosmo S.p.A. has completed an IPO in the amount of €22.999905 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 10,222,180
Price\Range: €2.25